Health Condition 1: C538- Malignant neoplasm of overlappingsites of cervix uteri
Conditions
Interventions
Intervention1: Far Infrared Imaging: Far infrared imaging at the time of brachytherapy for identification of residual disease. This imaging will be used to determine the presence of viable residual di
Sponsors
Department of Biotechnology
Eligibility
Inclusion criteria
Inclusion criteria: Biopsy proven carcinoma cervix patients who are planned for treatment with definitive concurrent chemoradiation using weekly Cisplatin. Histology: Squamous Cell Carcinoma, Adenosquamous carcinoma, Adenocarcinoma FIGO 2018 stage I - IIIC. Have pretreatment biopsy taken at Tata Medical Center or reviewed at Tata Medical Center.
Exclusion criteria
Exclusion criteria: Presence of any bleeding disorder Presence of idiopathic thrombocytopenic purpura or any other platelet disorder HIV Positivity Unavailable for follow up at Tata Medical Center. Patients who have undergone chemoradiation / radiation therapy outside. Presence of cochlear implant Presence of non-MRI safe implants and pacemakers Planned for palliative intent radiotherapy Stage IV patients Patients treated with neoadjuvant chemotherapy Prior history of radiation therapy to the pelvis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and Sepecificity of the device.Timepoint: Sensitivity and Sepecificity of the device. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the prognostic impact of the volume of residual abnormality in MRI (GTres) on: The clinical complete response rate on MRI at 3 months post-treatment. Timepoint: 3 months;Quantification of Tumor Infiltrating Lymphocytes in the biopsy specimens and PD-L1 expression in the tumor and immune cells. Timepoint: At brachytherapy;Determine the prognostic impact of the above parameters on disease-free survivalTimepoint: 3 years | — |
Countries
India
Contacts
Public ContactTapesh Bhattacharyya
Tata Medical Center
Outcome results
None listed